Dallas, TX -- (SBWire) -- 04/01/2015 --PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE:128940) has received marketing approval in Korea from the country's Ministry of Food and Drug Safety ("MFDS") and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis. Under the terms of the previously announced marketing agreement, Hanmi will import MuGard from the United States and marketing will commence. Hanmi intends to market MuGard in Korea under the trade name Mucogard.
Commenting on the news, Steven Rouhandeh, Executive Chairman of PlasmaTech Bio stated, "Hanmi receiving marketing approval is a critical step in the launch of MuGard in Korea and complements our broad commercialization strategy of MuGard in the global market. We look forward to working with them on next steps, including arrangement of commercial product, and leveraging their expertise and extensive distribution throughout the region."
"We are pleased with the continued progress being made on commercializing MuGard in Korea. We remain on track and look forward to providing doctors and patients in Korea access to MuGard, an effective treatment for oral mucositis, in 2015," stated by Dr. Gwan Sun Lee, President and Chief Executive Officer of Hanmi.
In 2014, PlasmaTech announced the publication of positive MuGard clinical data in Cancer, the journal of the American Cancer Society. The publication, entitled "Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for Cancers of the Head and Neck," is available to the public at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full
About Oral Mucositis
Oral mucositis ("OM") is a debilitating side effect of some radiation and chemotherapy cancer treatments, characterized by sores and ulcers in the mouth and throat that make swallowing difficult or impossible. It is estimated that 97% of patients receiving radiation for head and neck cancer, 70% of patients receiving stem cell transplantation and up to 40% of patients receiving conventional chemotherapy develop oral mucositis. There are an estimated 400,000 patients diagnosed with OM in the US annually, but OM is often under-diagnosed and the population at risk is significantly higher.
About MuGard
MuGard® Mucoadhesive Oral Wound Rinse is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces. MuGard is available by prescription only and is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation. MuGard received 510(k) clearance from the U.S. Food and Drug Administration and is marketed by AMAG Pharmaceuticals, Inc. in the United States. MuGard is licensed in Korea through Hanmi Pharmaceuticals and in Europe, Australia and New Zealand through Norgine, B.V.
About PlasmaTech
PlasmaTech is a biopharmaceutical company focused on advancing protein biologic therapies and oncology supportive care products. Exploiting two proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, and follow-on products in development.
For more information, visit http://www.plasmatechbio.com
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in PlasmaTech Bio's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.
